Profile picture of Scott Carruthers

Dr Scott Carruthers

Profile picture of Scott Carruthers

MBBS, FRANZCR

Radiation Oncologist
Call
Enquire
Referrals

I have a particular interest in continually bringing enhancement to the delivery of radiation therapy, through knowledge gained from clinical trials and advancements in technology, to provide our patients with the highest standards of care and best possible outcomes.

Biography

Dr Scott Carruthers is an experienced radiation oncologist consulting at Icon Cancer Centre Windsor Gardens. He completed his Bachelor of Medicine and Bachelor of Surgery (MBBS) at the University of Adelaide and completed specialist oncology training in Adelaide, with post graduate training in Melbourne and Edinburgh, United Kingdom.

In 1996, Dr Carruthers became a fellow of the Royal Australian and New Zealand College of Radiologists (RANZCR) and is an active member of several leading cancer trial groups including the American Society of Radiation Oncology (ASTRO), European Society for Radiotherapy and Oncology (ESTRO) and Australasian Brachytherapy Group (ABG).

Dr Carruthers enjoys a mixture of clinical work, contributing to leading cancer publications including The Lancet Oncology and Journal of Clinical Oncology and attending multidisciplinary meetings with his colleagues and medical community. Through a directorship with Northern Territory Radiation Oncology, Dr Carruthers has an ongoing support role with cancer care in the Northern Territory since 2010.

His clinical experience covers a broad range of solid tumour malignancies, with special clinical interest in breast, prostate, genitourinary, gastrointestinal and gynaecological cancers.

Publications

  • Total body irradiation and pneumonitis risk: a review of outcomes. S. Carruthers & M. Wallington. British Journal of Cancer, 2004. 90(11):2080-2084.

  • Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. M. Henderson, B. Burmeister, J. Ainslie, R. Fisher, J. Diiulio, Juliana, B. Smithers, A. Hong, K. Shannon, R. Scolyer, S. Carruthers, B. Coventry, S. Babington, J. Duprat, H. Hoekstra & J. Thompson. The Lancet Oncology, 2015.16(9).

  • Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life. M. Henderson, D. Gyorki, B. Burmeister, J. Ainslie, R. Fisher, J. Diiulio, B. Smithers, A. Hong, K. Shannon, R. Scolyer, S. Carruthers, B. Coventry, S. Babington, J. Duprat, H. Hoekstra & J. Thompson. Annals of Surgical Oncology, 2019. 26(36).

  • Measuring (and narrowing) the gap: The experience with attendance of Indigenous cancer patients for Radiation Therapy in the Northern Territory. S. Carruthers, M. Pennefather, L. Ward, K. Giam, & M. Penniment. Journal of Medical Imaging and Radiation Oncology, 2019. 63(4).

  • External evaluation of the Radiation Therapy Oncology Group brachial plexus contouring protocol: Several issues identified. M. Min, D. Roos, E. Keating, M. Penniment, S. Carruthers, L. Zanchetta, K. Wong, J. Shakeshaft & S. Baxi. Journal of Medical Imaging and Radiation Oncology, 2014. 58(3).

Special Interests

Dr Scott Carruthers accepts referrals for all cancer types, with a special clinical interest in:

  • Breast cancer
  • Colorectal cancer
  • Gastrointestinal cancer
  • Gynaecological cancer
  • Prostate cancer

Languages spoken

  • English

Affiliations & Memberships

  • Royal Australian and New Zealand College of Radiologists (RANZCR)
  • Australasian Brachytherapy Group (ABG)
  • American Society for Radiation Oncology (ASTRO)
  • Clinical Oncology Society of Australia (COSA)
  • European Society for Radiotherapy and Oncology (ESTRO)
  • Trans Tasman Radiation Oncology Group (TROG)

Publications

  • Total body irradiation and pneumonitis risk: a review of outcomes. S. Carruthers & M. Wallington. British Journal of Cancer, 2004. 90(11):2080-2084.

  • Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. M. Henderson, B. Burmeister, J. Ainslie, R. Fisher, J. Diiulio, Juliana, B. Smithers, A. Hong, K. Shannon, R. Scolyer, S. Carruthers, B. Coventry, S. Babington, J. Duprat, H. Hoekstra & J. Thompson. The Lancet Oncology, 2015.16(9).

  • Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life. M. Henderson, D. Gyorki, B. Burmeister, J. Ainslie, R. Fisher, J. Diiulio, B. Smithers, A. Hong, K. Shannon, R. Scolyer, S. Carruthers, B. Coventry, S. Babington, J. Duprat, H. Hoekstra & J. Thompson. Annals of Surgical Oncology, 2019. 26(36).

  • Measuring (and narrowing) the gap: The experience with attendance of Indigenous cancer patients for Radiation Therapy in the Northern Territory. S. Carruthers, M. Pennefather, L. Ward, K. Giam, & M. Penniment. Journal of Medical Imaging and Radiation Oncology, 2019. 63(4).

  • External evaluation of the Radiation Therapy Oncology Group brachial plexus contouring protocol: Several issues identified. M. Min, D. Roos, E. Keating, M. Penniment, S. Carruthers, L. Zanchetta, K. Wong, J. Shakeshaft & S. Baxi. Journal of Medical Imaging and Radiation Oncology, 2014. 58(3).

Search

Contact us
Become a patient